吉西他滨与培美曲塞联合卡铂治疗晚期肺腺癌的临床观察(1)
摘 要：目的 探討吉西他滨与培美曲塞联合卡铂治疗晚期肺腺癌的疗效及其对血癌胚抗原的影响。方法 选取2013年6月～2016年9月中山大学附属东华医院收治的晚期肺腺癌患者85例作为研究对象，随机分为对照组42例和观察组43例。在常规治疗基础上，对照组采用吉西他滨联合卡铂的化疗方案，观察组则采用培美曲塞联合卡铂的化疗方案。观察比较两组患者的治疗有效率，治疗前后的血清CEA以及不良反应的发生情况。结果 治疗后观察组治疗有效率为37.21%，对照组治疗有效率为30.95%，两组比较差异无统计学意义(P>0.05)。治疗前两组 CEA水平对比，差异无统计学意义(P>0.05)，治疗后观察组血CEA为(32.35±4.73)ng/ml，低于对照组(46.63±5.12)ng/ml，组间差异有统计学意义(P<0.05)。此外，观察组中性粒细胞减少、贫血以及血小板减少发生率低于对照组，差异有统计学意义(P<0.05)。结论 培美曲塞联合卡铂与吉西他滨联合卡铂治疗晚期肺腺癌患者的临床疗效相当，但培美曲塞组可明显降低血CEA水平，且不良反应发生率低，安全性好。
, 百拇医药
关键词：肺腺癌；吉西他滨；培美曲塞；卡铂；血CEA
中图分类号：R734.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.11.039
文章编号：1006-1959(2018)11-0124-04
Clinical Observation of Gemcitabine and Pemetrexed Combined with Carboplatin in Treatment of Advanced Lung Adenocarcinoma
PENG Yu-long，ZHANG Lu，CHEN Rong-hui，CAO Yong-xin，DENG Hui-jun
(Department of Oncology，Donghua Hospital Affiliated to Sun Yat-sen University，Dongguan 523110，Guangdong，China)
, 百拇医药
Abstract：Objective To investigate the efficacy of gemcitabine combined with pemetrexed combined with carboplatin in the treatment of advanced lung adenocarcinoma and its effect on hepatocarcinoembryonic antigen.Methods A total of 85 patients with advanced lung adenocarcinoma admitted to Donghua Hospital of Sun Yat-sen University from June 2013 to September 2016 were selected as study objects.They were randomly divided into a control group of 42 cases and an observation group of 43 cases.On the basis of conventional treatment，the control group received a chemotherapy regimen of gemcitabine plus carboplatin，while the observation group used a chemotherapy regimen of pemetrexed combined with carboplatin.The efficacy of treatment，the serum CEA before and after treatment，and the occurrence of adverse reactions were observed and compared between the two groups.Results After treatment，the effective rate was 37.21% in the observation group and 30.95% in the control group.There was no significant difference between the two groups(P>0.05).There was no significant difference in CEA levels between the two groups before treatment(P>0.05). After treatment，CEA in the observation group was(32.35±4.73)ng/ml，which was lower than that of the control group(46.63±5.12)ng/ml. There was a statistically significant difference between groups(P<0.05).In addition，the incidence of neutropenia，anemia，and thrombocytopenia was lower in the observation group than in the control group，with a significant difference(P<0.05).Conclusion The clinical efficacy of pemetrexed combined with carboplatin and gemcitabine combined with carboplatin in the treatment of advanced lung adenocarcinoma is similar，but pemetrexed can significantly reduce blood CEA levels，and the incidence of adverse reactions is low， and safety is good., 百拇医药(彭玉龙 张露 陈荣辉 曹永新 邓惠君)
, 百拇医药
关键词：肺腺癌；吉西他滨；培美曲塞；卡铂；血CEA
中图分类号：R734.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.11.039
文章编号：1006-1959(2018)11-0124-04
Clinical Observation of Gemcitabine and Pemetrexed Combined with Carboplatin in Treatment of Advanced Lung Adenocarcinoma
PENG Yu-long，ZHANG Lu，CHEN Rong-hui，CAO Yong-xin，DENG Hui-jun
(Department of Oncology，Donghua Hospital Affiliated to Sun Yat-sen University，Dongguan 523110，Guangdong，China)
, 百拇医药
Abstract：Objective To investigate the efficacy of gemcitabine combined with pemetrexed combined with carboplatin in the treatment of advanced lung adenocarcinoma and its effect on hepatocarcinoembryonic antigen.Methods A total of 85 patients with advanced lung adenocarcinoma admitted to Donghua Hospital of Sun Yat-sen University from June 2013 to September 2016 were selected as study objects.They were randomly divided into a control group of 42 cases and an observation group of 43 cases.On the basis of conventional treatment，the control group received a chemotherapy regimen of gemcitabine plus carboplatin，while the observation group used a chemotherapy regimen of pemetrexed combined with carboplatin.The efficacy of treatment，the serum CEA before and after treatment，and the occurrence of adverse reactions were observed and compared between the two groups.Results After treatment，the effective rate was 37.21% in the observation group and 30.95% in the control group.There was no significant difference between the two groups(P>0.05).There was no significant difference in CEA levels between the two groups before treatment(P>0.05). After treatment，CEA in the observation group was(32.35±4.73)ng/ml，which was lower than that of the control group(46.63±5.12)ng/ml. There was a statistically significant difference between groups(P<0.05).In addition，the incidence of neutropenia，anemia，and thrombocytopenia was lower in the observation group than in the control group，with a significant difference(P<0.05).Conclusion The clinical efficacy of pemetrexed combined with carboplatin and gemcitabine combined with carboplatin in the treatment of advanced lung adenocarcinoma is similar，but pemetrexed can significantly reduce blood CEA levels，and the incidence of adverse reactions is low， and safety is good., 百拇医药(彭玉龙 张露 陈荣辉 曹永新 邓惠君)